uniQure N.V. announced its plan to submit a Biologic License Application (BLA) for AMT-130 in Huntington's Disease during the third quarter of 2026. This follows a Type B meeting with the FDA, where the agency communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis for an accelerated approval. uniQure N.V. is a biotechnology company focused on developing gene therapies for rare genetic diseases.
